Checkpoint Nano‐PROTACs for Activatable Cancer Photo‐Immunotherapy
Authors:
- 18 December 2022
- journal article
- research article
- Published by Wiley in Advanced Materials
- Vol. 35 (6) , e2208553
Abstract
Checkpoint immunotherapy holds great potential to treat malignancies via blocking the immunosuppressive signaling pathways, which however suffers from inefficiency and off‐target adverse effects. Herein, checkpoint nano‐proteolysis targeting chimeras (nano‐PROTACs) in combination with photodynamic tumor regression and immunosuppressive protein degradation to block checkpoint signaling pathways for activatable cancer photo‐immunotherapy are reported. These nano‐PROTACs are composed of a photosensitizer (protoporphyrin IX, PpIX) and an Src homology 2 domain‐containing phosphatase 2 (SHP2)‐targeting PROTAC peptide (aPRO) via a caspase 3‐cleavable segment. aPRO is activated by the increased expression of caspase 3 in tumor cells after phototherapeutic treatment and induces targeted degradation of SHP2 via the ubiquitin‐proteasome system. The persistent depletion of SHP2 blocks the immunosuppressive checkpoint signaling pathways (CD47/SIRPα and PD‐1/PD‐L1), thus reinvigorating antitumor macrophages and T cells. Such a checkpoint PROTAC strategy synergizes immunogenic phototherapy to boost antitumor immune response. Thus, this study represents a generalized PROTAC platform to modulate immune‐related signaling pathways for improved anticancer therapy.Keywords
This publication has 53 references indexed in Scilit:
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillanceNature Reviews Clinical Oncology, 2019
- Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in miceNature Communications, 2019
- Cancer nanomedicine for combination cancer immunotherapyNature Reviews Materials, 2019
- SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsNature Medicine, 2018
- Enhanced Immunotherapy Based on Photodynamic Therapy for Both Primary and Lung Metastasis Tumor EradicationACS Nano, 2018
- Induced protein degradation: an emerging drug discovery paradigmNature Reviews Drug Discovery, 2016
- Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapyNature Communications, 2016
- Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinasesNature, 2016
- SCF ubiquitin ligase-targeted therapiesNature Reviews Drug Discovery, 2014
- Diversity of degradation signals in the ubiquitin–proteasome systemNature Reviews Molecular Cell Biology, 2008